Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder
Autore:
Spencer, T; Biederman, J; Heiligenstein, J; Wilens, T; Faries, D; Prince, J; Faraone, SV; Rea, J; Witcher, J; Zervas, S;
Indirizzi:
Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 col Unit, Boston, MA 02114 USA Lilly Res Labs, Indianapolis, IN USA Lilly Res Labs Indianapolis IN USALilly Res Labs, Indianapolis, IN USA
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 11, anno: 2001,
pagine: 251 - 265
SICI:
1044-5463(200123)11:3<251:AODSOA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOPAMINE D4 RECEPTOR; DEFICIT/HYPERACTIVITY DISORDER; STIMULANT MEDICATION; CONTROLLED TRIAL; DOUBLE-BLIND; ADHD; METHYLPHENIDATE; ADULTS; GENE; DESIPRAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Spencer, T Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, ACC-725,15Parkman St, Boston, MA 02114 USA Massachusetts Gen Hosp ACC-725,15 ParkmanSt Boston MA USA 02114
Citazione:
T. Spencer et al., "An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder", J CH AD PSY, 11(3), 2001, pp. 251-265

Abstract

Objective: The goal of this study was to evaluate the tolerability and effectiveness of the experimental, noradrenergic specific reuptake inhibitor atomoxetine in the treatment of children with attention deficit hyperactivity disorder (ADHD). Methods: This was an open, prospective, dose-ranging study of atomoxetine monotherapy in the treatment of 30 children with ADHD between the ages of 7and 14 years. Atomoxetine was started at 10-20 mg/day and titrated weekly up to 90 mg over 11 weeks, depending on response and adverse effects. Twenty-two children completed the full 11 weeks. We assessed efficacy with weekly clinician and parent ratings of ADHD and oppositional symptoms and monitored adverse effects, laboratory findings, and cardiovascular parameters. Results: Treatment with atomoxetine (mean final, total daily dose of 1.9 mg/kg/day) was very well tolerated without meaningful adverse effects. Atomoxetine significantly reduced core symptoms of ADHD (ADHD-Rating Scale-IV; 38.6% decrease vs. baseline, p < 0.001) with significant improvement (p < 0.05) in all but 1 of the 18 individual items in the ADHD-Rating Scale-IV. More than 75% of subjects who completed 10 weeks of treatment showed > 25% decrease in ADHD symptoms. Conclusions: These findings extend to children the positive results previously reported in adults diagnosed with ADHD who were treated with atomoxetine. These results support additional controlled trials of atomoxetine in cases of pediatric ADHD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 21:49:45